[Advances in the Treatment of Acute Myeloid Leukemia with TP53 Mutations-Review]

Acute myeloid leukemia (AML) is the most common hematological malignancies in adults. TP53, as a tumor suppressor gene, has a mutation rate of about 5%-10% in AML patients. In 2017, the European Leukemia Net first classified AML with TP53 mutations as an unfavorable risk group, highlighting its importance of its importance in predicting prognosis. Currently, the treatment for TP53-mutated AML mainly includes intensive chemotherapy, demethylating therapy, and allogeneic hematopoietic stem cell transplantation. In recent years, with the application of new treatment methods such as immunotherapy and targeted drugs, the survival rate of patients has been improved to some extent. Overall, the efficacy and prognosis of TP53-mutated AML are poor, but there is a certain heterogeneity in the efficacy and survival of these patients. This article reviews the main pathogenesis and the latest treatment progress of AML with TP53 gene mutations, aiming to provide reference for clinical diagnosis and treatment.